UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 78

Sortiert nach

Endometrial Hyperplasia

Obstetrics and gynecology (New York. 1953), 2022-12, Vol.140 (6), p.1061

2022

Volltextzugriff (PDF)

PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors

The American journal of surgical pathology, 2017-03, Vol.41 (3), p.326-333

2017

Volltextzugriff (PDF)

How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations

Gynecologic oncology, 2024-05, Vol.184, p.8-15

2024

Volltextzugriff (PDF)

TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers

Modern pathology, 2019-08, Vol.32 (8), p.1168-1179

2019

Volltextzugriff (PDF)

Updates in gynecologic care for individuals with lynch syndrome

Frontiers in oncology, 2023-03, Vol.13, p.1127683-1127683

2023

Volltextzugriff (PDF)

Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists

Modern pathology, 2022-02, Vol.35 (2), p.142-151

2022

Volltextzugriff (PDF)

Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors

Gynecologic oncology, 2017-03, Vol.144 (3), p.607-612

2017

Volltextzugriff (PDF)

Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas

Modern pathology, 2018-08, Vol.31 (8), p.1282-1290

2018

Volltextzugriff (PDF)

Role of Minimally Invasive Surgery in Gynecologic Oncology: An Updated Survey of Members of the Society of Gynecologic Oncology

International journal of gynecological cancer, 2015-07, Vol.25 (6), p.1121-1127

2015

Volltextzugriff (PDF)

Current and future role of genetic screening in gynecologic malignancies

American journal of obstetrics and gynecology, 2017-11, Vol.217 (5), p.512-521

2017

Volltextzugriff (PDF)

LAG-3 and GAL-3 in Endometrial Carcinoma: Emerging Candidates for Immunotherapy

International journal of gynecological pathology, 2020-05, Vol.39 (3), p.203

2020

Volltextzugriff (PDF)

The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies

Current treatment options in oncology, 2018-12, Vol.19 (12), p.70, Article 70

2018

Volltextzugriff (PDF)

Somatic Sequencing and Microsatellite Instability Results From Mismatch Repair-deficient Endometrial Carcinoma Patients Without Lynch Syndrome ("Lynch-like" tumors): Implications for Heritable Cancer Screening, Molecular Prognostication, and Immunotherapeutic Vulnerability

The American journal of surgical pathology, 2023-08, Vol.47 (8), p.878

2023

Volltextzugriff (PDF)

A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response

Clinical cancer research, 2021-05, Vol.27 (10), p.2734-2741

2021

Volltextzugriff (PDF)

MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition

Modern pathology, 2021-03, Vol.34 (3), p.627-636

2021

Volltextzugriff (PDF)

Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort

Modern pathology, 2016-11, Vol.29 (11), p.1381-1389

2016

Volltextzugriff (PDF)

Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy

Frontiers in immunology, 2018-09, Vol.9, p.2102-2102

2018

Volltextzugriff (PDF)

An Enteropathy-like Indolent NK-Cell Proliferation Presenting in the Female Genital Tract

The American journal of surgical pathology, 2020-04, Vol.44 (4), p.561

2020

Volltextzugriff (PDF)

One size may not fit all: The debate of universal tumor testing for Lynch syndrome

Gynecologic oncology, 2015-04, Vol.137 (1), p.2-3

2015

Volltextzugriff (PDF)

Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer

Cancer prevention research (Philadelphia, Pa.), 2017-02, Vol.10 (2), p.108-115

2017

Volltextzugriff (PDF)

Clinical significance of homologous recombination deficiency score testing in endometrial Cancer

Gynecologic oncology, 2021-03, Vol.160 (3), p.777-785

2021

Volltextzugriff (PDF)

PD-L1 and MHC Class I Expression in High-grade Ovarian Cancers, Including Platinum-resistant Recurrences Treated With Checkpoint Inhibitor Therapy

Applied immunohistochemistry & molecular morphology, 2023-04, Vol.31 (4), p.197

2023

Volltextzugriff (PDF)

Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for lynch syndrome

Gynecologic oncology, 2014-08, Vol.134 (2), p.319-325

2014

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies

The cancer journal (Sudbury, Mass.), 2016-03, Vol.22 (2), p.101

2016

Volltextzugriff (PDF)

MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status

International journal of gynecological pathology, 2022-01, Vol.41 (1), p.1

2022

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(57)

Publikationsform

Sprache

Englisch
(78)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Endometrial Hyperplasia

PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors

How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations

TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers

Updates in gynecologic care for individuals with lynch syndrome

Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists

Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors

Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas

Role of Minimally Invasive Surgery in Gynecologic Oncology: An Updated Survey of Members of the Society of Gynecologic Oncology

Current and future role of genetic screening in gynecologic malignancies

LAG-3 and GAL-3 in Endometrial Carcinoma: Emerging Candidates for Immunotherapy

The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies

Somatic Sequencing and Microsatellite Instability Results From Mismatch Repair-deficient Endometrial Carcinoma Patients Without Lynch Syndrome ("Lynch-like" tumors): Implications for Heritable Cancer Screening, Molecular Prognostication, and Immunotherapeutic Vulnerability

A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response

MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition

Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort

Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy

An Enteropathy-like Indolent NK-Cell Proliferation Presenting in the Female Genital Tract

One size may not fit all: The debate of universal tumor testing for Lynch syndrome

Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer

Clinical significance of homologous recombination deficiency score testing in endometrial Cancer

PD-L1 and MHC Class I Expression in High-grade Ovarian Cancers, Including Platinum-resistant Recurrences Treated With Checkpoint Inhibitor Therapy

Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for lynch syndrome

Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies

MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status

Suchergebnisse filtern